BioCentury
ARTICLE | Clinical News

RT002: Phase II started

October 5, 2015 7:00 AM UTC

Revance began an open-label, dose-escalation, U.S. Phase II trial to evaluate 3 dose levels of a single intramuscular injection of RT002 in about 36 patients. ...